Study details
Enrolling now
Abelacimab Trial in AF Patients
Anthos Therapeutics, Inc.
NCT IDNCT05712200ClinicalTrials.gov data as of Apr 2026
Phase
Phase 3
Target enrollment
1,900
Study length
about 3.8 years
Ages
65+
Locations
150 sites in AL, AZ, CA +30
What this study is about
Researchers are testing if abelacimab, a treatment, is effective and safe compared to placebo for people with atrial fibrillation who can't take oral blood thinners. The trial will last 1404 days.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive Abelacimab
- 2.Take Placebo
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
Randomized & Blinded
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
monoclonal antibody
Body systems
Cardiology / Heart